Shift in obesity care is on the horizon … Greater access. G…

Shift in obesity care is on the horizon …

Greater access. Greater affordability. Greater impact.

At least 1 in 3 people living with obesity worldwide will reside in countries with access to off-patent Semaglutide that has the potential to make obesity treatment more accessible and affordable for millions.

As access expands, there is an opportunity to reach more patients with evidence-based obesity management, helping bridge treatment gaps and improve long-term health outcomes.

Source

Thought Leadership, IQVIA.